Definium Therapeutics, Inc.

DFTX

As of the close on Sep 25, 2026

Price

$36.17

Market cap

—

The cover-page share count does not match the latest report's share count

P/E (diluted TTM)

—

A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given

EPS (TTM)

—

A per-share figure for one of the last four quarters is not shown, so no four-quarter total is given

Dividend yield

—

Dividend records do not yet cover the latest payments

Figures shown here come from public SEC filings. Dates beside each section show the available history.

How Definium Therapeutics, Inc. Makes Money

No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.

Financial Summary

Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.

Loading financial history…

SEC filings supply these figures; updates after the dates shown are not included. This page includes 7 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 26, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Reported 13F positions

Each row shows what a filer reported for one date, not a current position. The link opens that filing.

No 13F rows are listed for Definium Therapeutics, Inc.

8 rows left out: they repeat the same share count and value quarter after quarter, which a market value cannot do.

Unusually large insider trades

Each trade is compared with the other insider trades of the same kind in the same security among Definium Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.

2026-06-25 · Barrow Robert: Larger than 70 of the 71 other insider sales of Common Shares on file. SEC filing
2026-03-25 · Barrow Robert: Larger than 65 of the 71 other insider sales of Common Shares on file. SEC filing
2025-12-26 · Barrow Robert: Larger than 66 of the 71 other insider sales of Common Shares on file. SEC filing
2025-09-25 · Barrow Robert: Larger than 67 of the 71 other insider sales of Common Shares on file. SEC filing
2025-06-25 · Barrow Robert: Larger than 69 of the 71 other insider sales of Common Shares on file. SEC filing
2022-06-27 · Barrow Robert: Larger than all 71 other insider sales of Common Shares on file. SEC filing
2022-06-27 · Karlin Dan: Larger than 68 of the 71 other insider sales of Common Shares on file. SEC filing
2022-06-16 · Barrow Robert: Larger than 64 of the 71 other insider sales of Common Shares on file. SEC filing

Independent insiders buying near the same time

2024-08-19–2024-08-23: 3 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing )

Purchases & sales (open market or private)

		Security	Code		Price	Filing
2026-06-25	Roberts Brandi · Chief Financial Officer	Common Shares	S — Open market or private sale	−3,013	45.03	SEC filing
2026-06-25	Wiley Matthew T. · Chief Commercial Officer	Common Shares	S — Open market or private sale	−2,867	45.03	SEC filing
2026-06-25	Sullivan Mark · Chief Legal Officer	Common Shares	S — Open market or private sale	−13,008	45.03	SEC filing
2026-06-25	Barrow Robert · Chief Executive Officer	Common Shares	S — Open market or private sale	−29,208	45.03	SEC filing
2026-06-25	Karlin Daniel · Chief Medical Officer	Common Shares	S — Open market or private sale	−10,035	45.03	SEC filing
2026-03-25	Karlin Daniel · Chief Medical Officer	Common Shares	S — Open market or private sale	−8,018	18.47	SEC filing
2026-03-25	Barrow Robert · Chief Executive Officer	Common Shares	S — Open market or private sale	−24,431	18.47	SEC filing
2026-03-25	Sullivan Mark · Chief Legal Officer	Common Shares	S — Open market or private sale	−10,702	18.47	SEC filing

Showing 8 of 14 rows

Grants, exercises, tax & gifts

		Security	Code		Filing
2026-06-22	Sullivan Mark · Chief Legal Officer	Common Shares	A — Grant, award, or other acquisition	+62,500	SEC filing
2026-06-22	Barrow Robert · Chief Executive Officer	Common Shares	A — Grant, award, or other acquisition	+375,000	SEC filing
2026-06-22	Karlin Daniel · Chief Medical Officer	Common Shares	A — Grant, award, or other acquisition	+100,000	SEC filing
2026-06-22	Wiley Matthew T. · Chief Commercial Officer	Common Shares	A — Grant, award, or other acquisition	+62,500	SEC filing
2026-06-22	Roberts Brandi · Chief Financial Officer	Common Shares	A — Grant, award, or other acquisition	+62,500	SEC filing
2026-06-11	Adsett Roger · Director	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+14,620	SEC filing
2026-06-11	Vallone Carol A · Director	Stock Option (Right to Buy)	A — Grant, award, or other acquisition	+19,188	SEC filing
2026-06-11	Adsett Roger · Director	Common Shares	A — Grant, award, or other acquisition	+3,555	SEC filing

Showing 8 of 22 rows

Other activity

		Security	Code		Filing
2022-05-11	Makes Brigid · Director	Subordinate Voting Shares	J — Other acquisition or disposition	+67,678	SEC filing

Showing 1 of 1 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.